Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.260
-0.020 (-0.88%)
At close: Dec 5, 2025, 4:00 PM EST
2.261
+0.001 (0.05%)
After-hours: Dec 5, 2025, 4:18 PM EST
Spero Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Spero Therapeutics stock have an average target of 5.00, which predicts an increase of 121.24% from the current stock price of 2.26.
Analyst Consensus: Buy
* Price targets were last updated on Jan 30, 2025.
Analyst Ratings
The average analyst rating for Spero Therapeutics stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 1 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +121.24% | Jan 30, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy → Hold Downgrades $5 | Buy → Hold | Downgrades | $5 | +121.24% | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +121.24% | Dec 2, 2024 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 18, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Nov 15, 2024 |
Financial Forecast
Revenue This Year
26.01M
from 47.98M
Decreased by -45.79%
Revenue Next Year
816.00K
from 26.01M
Decreased by -96.86%
EPS This Year
-0.40
from -1.27
EPS Next Year
0.02
from -0.40
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 26.8M | 840,000 | ||||
| Avg | 26.0M | 816,000 | ||||
| Low | 25.0M | 784,000 |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -44.2% | -96.8% | ||||
| Avg | -45.8% | -96.9% | ||||
| Low | -47.9% | -97.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.14 | 0.70 | |
| Avg | -0.40 | 0.02 | |
| Low | -0.64 | -0.63 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.